tetano
Editor, Senior Moderator
J Infect Dis
. 2020 Dec 1;jiaa743.
doi: 10.1093/infdis/jiaa743. Online ahead of print.
D614G Spike Variant Does Not Alter IgG, IgM, or IgA Spike Seroassay Performance
Carleen Klumpp-Thomas[SUP] 1 2 [/SUP], Heather Kalish[SUP] 3 [/SUP], Jennifer Hicks[SUP] 3 [/SUP], Jennifer Mehalko[SUP] 4 [/SUP], Matthew Drew[SUP] 4 [/SUP], Matthew J Memoli[SUP] 5 [/SUP], Matthew D Hall[SUP] 1 [/SUP], Dominic Esposito[SUP] 4 [/SUP], Kaitlyn Sadtler[SUP] 2 [/SUP]
Affiliations
Abstract
Emergence of a new spike protein variant (D614G) with increased infectivity has prompted many to analyze its role in the SARS-CoV-2 pandemic. There is concern regarding whether an individual exposed to one variant of a virus will have cross-reactive memory to the second. Accordingly, we analyzed the serologic reactivity of both variants, and found that antibodies from 88 donors from a high-incidence population reacted toward both the original spike and the D614 spike variant. These data suggest patients who are exposed to either variant have cross-responsive humoral immunity. This represents an important finding both for SARS-CoV-2 disease biology and for therapeutics.
Keywords: COVID-19; D614G; SARS-CoV-2; coronavirus; pandemic; spike protein.
. 2020 Dec 1;jiaa743.
doi: 10.1093/infdis/jiaa743. Online ahead of print.
D614G Spike Variant Does Not Alter IgG, IgM, or IgA Spike Seroassay Performance
Carleen Klumpp-Thomas[SUP] 1 2 [/SUP], Heather Kalish[SUP] 3 [/SUP], Jennifer Hicks[SUP] 3 [/SUP], Jennifer Mehalko[SUP] 4 [/SUP], Matthew Drew[SUP] 4 [/SUP], Matthew J Memoli[SUP] 5 [/SUP], Matthew D Hall[SUP] 1 [/SUP], Dominic Esposito[SUP] 4 [/SUP], Kaitlyn Sadtler[SUP] 2 [/SUP]
Affiliations
- PMID: 33257936
- DOI: 10.1093/infdis/jiaa743
Abstract
Emergence of a new spike protein variant (D614G) with increased infectivity has prompted many to analyze its role in the SARS-CoV-2 pandemic. There is concern regarding whether an individual exposed to one variant of a virus will have cross-reactive memory to the second. Accordingly, we analyzed the serologic reactivity of both variants, and found that antibodies from 88 donors from a high-incidence population reacted toward both the original spike and the D614 spike variant. These data suggest patients who are exposed to either variant have cross-responsive humoral immunity. This represents an important finding both for SARS-CoV-2 disease biology and for therapeutics.
Keywords: COVID-19; D614G; SARS-CoV-2; coronavirus; pandemic; spike protein.